NCT00499122View on ClinicalTrials.gov

NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 4, 2007

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

Breast Cancer

Interventions

DRUG

Cyclophosphamide

DRUG

Docetaxel

DRUG

Doxorubicin

DRUG

NOV 002

Trial Locations (2)

29425

Hollings Cancer Center at Medical University of South Carolina, Charleston

33136

University of Miami, Miami

All Listed Sponsors

lead

University of Miami

OTHER

NCT00499122 - NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer | Biotech Hunter | Biotech Hunter